Research programme: eye disorder therapeutics - GrayBugAlternative Names: GB-102; Sunitinib maleate depot - GrayBug
Latest Information Update: 10 May 2016
Price : $50
At a glance
- Originator GrayBug inc.
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Platelet-derived growth factor inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factors inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Eye disorders